Founded in 1975, Israel Cancer Research Fund (ICRF) is the largest nongovernmental source of funding dedicated solely to cancer research in Israel. Through a rigorous international peer-review process, ICRF funds promising scientists and innovative studies across Israel’s leading universities, hospitals, and research institutions.


To date, ICRF has raised more than $100 million USD, awarded nearly 3,000 grants, and supported discoveries that have helped shape cancer diagnosis, treatment, and care worldwide. With the continued support of donors and partners, ICRF remains committed to advancing life-saving research and bringing us closer to a future without cancer.

OUR SUCCESSES

GLEEVEC

The development of Gleevec (imatinib) marked a turning point in cancer care, transforming chronic myelogenous leukemia into a manageable disease for more than 200,000 people worldwide.

P53 GENE

p53, known as the “guardian of the genome,” stands as one of the most important scientific discoveries of the 20th century, with mutations found in approximately 50% of all human tumors.

UBIQUITIN SYSTEM

The groundbreaking discovery of the ubiquitin–proteasome system led to Velcade, a transformative treatment for multiple myeloma, and was recognized with the 2004 Nobel Prize in Chemistry.

DOXIL

The first liposomal (fat-encapsulated) chemotherapy agent, offering longer circulation and reduced toxicity. It is now used in treating ovarian cancer, AIDS-related Kaposi’s sarcoma, and other cancers.